Business Context and Reporting Period
Company: Intensity Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 4, 2025
Reporting Period: Event-specific report dated December 4, 2025.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes
- ATM Program Expansion: The Company filed a prospectus supplement to increase the capacity of its existing "at-the-market" (ATM) offering program to $30 million.
- Agreement Details: The program is conducted pursuant to an Offering Agreement dated July 3, 2024, with H.C. Wainwright & Co. LLC as the Sales Agent.
- Discretionary Nature: The Company is under no obligation to issue shares under this expanded facility. Utilization depends on market conditions and strategic priorities.
Guidance, Outlook, and Risks
- Management Commentary: The expanded facility is intended to enhance financial flexibility and provide an efficient mechanism to access capital if deemed appropriate.
- Risks and Contingencies: There can be no assurance that the Sales Agent will be able to complete future placements even if instructed. The number of shares sold will fluctuate based on market price, sales limits, and demand.
- Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the current outstanding share count to assess potential dilution if the full $30 million ATM capacity is utilized.
- Review the Company's most recent 10-Q or 10-K for actual cash runway and liquidity status, as this 8-K does not provide those figures.
- Monitor future filings for actual sales activity under the ATM program, as the filing confirms no obligation to sell.
- Check the prevailing market price of INTS common stock to estimate the potential number of shares issuable under the $30 million cap.